Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72


Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis.

McReynolds CB, Hwang SH, Yang J, Wan D, Wagner K, Morisseau C, Li D, Schmidt WK, Hammock BD.

Front Pharmacol. 2019 May 31;10:533. doi: 10.3389/fphar.2019.00533. eCollection 2019.


Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach.

Webster L, Schmidt WK.

Pain Med. 2019 Jun 5. pii: pnz122. doi: 10.1093/pm/pnz122. [Epub ahead of print]


Protein Isoprenylation in Yeast Targets COOH-Terminal Sequences Not Adhering to the CaaX Consensus.

Berger BM, Kim JH, Hildebrandt ER, Davis IC, Morgan MC, Hougland JL, Schmidt WK.

Genetics. 2018 Dec;210(4):1301-1316. doi: 10.1534/genetics.118.301454. Epub 2018 Sep 26.


The opioid crisis and … reconsidering the use of drugs that affect body temperature.

Patwardhan A, Porreca F, Schmidt WK, Romanovsky AA.

Temperature (Austin). 2018 Mar 6;5(1):1-3. doi: 10.1080/23328940.2018.1437312. eCollection 2018. No abstract available.


Rce1: mechanism and inhibition.

Hampton SE, Dore TM, Schmidt WK.

Crit Rev Biochem Mol Biol. 2018 Apr;53(2):157-174. doi: 10.1080/10409238.2018.1431606. Epub 2018 Feb 9. Review.


Efficient farnesylation of an extended C-terminal C(x)3X sequence motif expands the scope of the prenylated proteome.

Blanden MJ, Suazo KF, Hildebrandt ER, Hardgrove DS, Patel M, Saunders WP, Distefano MD, Schmidt WK, Hougland JL.

J Biol Chem. 2018 Feb 23;293(8):2770-2785. doi: 10.1074/jbc.M117.805770. Epub 2017 Dec 27.


Turning up the heat on surgical cold.

Schmidt WK.

Temperature (Austin). 2017 Apr 14;4(2):97-100. doi: 10.1080/23328940.2017.1319453. eCollection 2017. No abstract available.


Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.

Wagner KM, McReynolds CB, Schmidt WK, Hammock BD.

Pharmacol Ther. 2017 Dec;180:62-76. doi: 10.1016/j.pharmthera.2017.06.006. Epub 2017 Jun 19. Review.


In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone.

Kirkpatrick DL, Schmidt WK, Morales R, Cremin J, Seroogy J, Husfeld C, Jenkins T.

J Opioid Manag. 2017 Jan/Feb;13(1):39-49. doi: 10.5055/jom.2017.0366.


Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines.

Pergolizzi JV Jr, Raffa RB, Zampogna G, Breve F, Colucci R, Schmidt WK, LeQuang JA.

Pain Pract. 2016 Sep;16(7):794-808. doi: 10.1111/papr.12475. No abstract available.


A shunt pathway limits the CaaX processing of Hsp40 Ydj1p and regulates Ydj1p-dependent phenotypes.

Hildebrandt ER, Cheng M, Zhao P, Kim JH, Wells L, Schmidt WK.

Elife. 2016 Aug 15;5. pii: e15899. doi: 10.7554/eLife.15899.


Ste24p Mediates Proteolysis of Both Isoprenylated and Non-prenylated Oligopeptides.

Hildebrandt ER, Arachea BT, Wiener MC, Schmidt WK.

J Biol Chem. 2016 Jul 1;291(27):14185-98. doi: 10.1074/jbc.M116.718197. Epub 2016 Apr 29.


A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuroma.

Campbell CM, Diamond E, Schmidt WK, Kelly M, Allen R, Houghton W, Brady KL, Campbell JN.

Pain. 2016 Jun;157(6):1297-304. doi: 10.1097/j.pain.0000000000000544.


8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells.

Mohammed I, Hampton SE, Ashall L, Hildebrandt ER, Kutlik RA, Manandhar SP, Floyd BJ, Smith HE, Dozier JK, Distefano MD, Schmidt WK, Dore TM.

Bioorg Med Chem. 2016 Jan 15;24(2):160-78. doi: 10.1016/j.bmc.2015.11.043. Epub 2015 Nov 30.


An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome pain.

Harper WL, Schmidt WK, Kubat NJ, Isenberg RA.

Int Med Case Rep J. 2014 Dec 31;8:13-22. doi: 10.2147/IMCRJ.S73068. eCollection 2015.


Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury.

Mamet J, Klukinov M, Yaksh TL, Malkmus SA, Williams S, Harris S, Manning DC, Taylor BK, Donahue RR, Porreca F, Xie JY, Oyarzo J, Brennan TJ, Subieta A, Schmidt WK, Yeomans DC.

Pain. 2014 Feb;155(2):322-33. doi: 10.1016/j.pain.2013.10.015. Epub 2013 Oct 18.


Topology of the yeast Ras converting enzyme as inferred from cysteine accessibility studies.

Hildebrandt ER, Davis DM, Deaton J, Krishnankutty RK, Lilla E, Schmidt WK.

Biochemistry. 2013 Sep 24;52(38):6601-14. doi: 10.1021/bi400647c. Epub 2013 Sep 10.


Evaluating amyloid Beta (aβ) 1-40 degradation by capillary electrophoresis.

Alper BJ, Schmidt WK.

Methods Mol Biol. 2013;984:263-73. doi: 10.1007/978-1-62703-296-4_19.


Cell-permeable, small-molecule activators of the insulin-degrading enzyme.

Kukday SS, Manandhar SP, Ludley MC, Burriss ME, Alper BJ, Schmidt WK.

J Biomol Screen. 2012 Dec;17(10):1348-61. doi: 10.1177/1087057112451921. Epub 2012 Jun 26.


Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy.

Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, Petersen KL, Rowbotham MC, Campbell JN.

Pain. 2012 Sep;153(9):1815-23. doi: 10.1016/j.pain.2012.04.014. Epub 2012 Jun 8.


Evaluating therapeutic benefit in postsurgical analgesia requires global assessment: an example from liposome bupivacaine in hemorrhoidectomy.

Schmidt WK, Patou G, Joshi GP.

Hosp Pract (1995). 2012 Feb;40(1):160-5. doi: 10.3810/hp.2012.02.956.


Photoaffinity labeling of Ras converting enzyme using peptide substrates that incorporate benzoylphenylalanine (Bpa) residues: improved labeling and structural implications.

Kyro K, Manandhar SP, Mullen D, Schmidt WK, Distefano MD.

Bioorg Med Chem. 2011 Dec 15;19(24):7559-69. doi: 10.1016/j.bmc.2011.10.027. Epub 2011 Oct 18.


Anion activation site of insulin-degrading enzyme.

Noinaj N, Song ES, Bhasin S, Alper BJ, Schmidt WK, Hersh LB, Rodgers DW.

J Biol Chem. 2012 Jan 2;287(1):48-57. doi: 10.1074/jbc.M111.264614. Epub 2011 Nov 2.


Onset of action of diclofenac potassium liquid-filled capsules in dental surgery patients.

Zuniga JR, Noveck RJ, Schmidt WK, Boesing SE, Hersh EV.

Curr Med Res Opin. 2011 Sep;27(9):1733-9. doi: 10.1185/03007995.2011.600300. Epub 2011 Jul 19.


Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteases.

Dechert AM, MacNamara JP, Breevoort SR, Hildebrandt ER, Hembree NW, Rea AC, McLain DE, Porter SB, Schmidt WK, Dore TM.

Bioorg Med Chem. 2010 Sep 1;18(17):6230-7. doi: 10.1016/j.bmc.2010.07.041. Epub 2010 Jul 21.


Photoaffinity labeling of Ras converting enzyme 1 (Rce1p) using a benzophenone-containing peptide substrate.

Kyro K, Manandhar SP, Mullen D, Schmidt WK, Distefano MD.

Bioorg Med Chem. 2010 Aug 1;18(15):5675-84. doi: 10.1016/j.bmc.2010.06.024. Epub 2010 Jun 12.


Chemical inhibition of CaaX protease activity disrupts yeast Ras localization.

Manandhar SP, Hildebrandt ER, Jacobsen WH, Santangelo GM, Schmidt WK.

Yeast. 2010 Jun;27(6):327-43. doi: 10.1002/yea.1756.


Heterologous expression studies of Saccharomyces cerevisiae reveal two distinct trypanosomatid CaaX protease activities and identify their potential targets.

Mokry DZ, Manandhar SP, Chicola KA, Santangelo GM, Schmidt WK.

Eukaryot Cell. 2009 Dec;8(12):1891-900. doi: 10.1128/EC.00169-09. Epub 2009 Oct 9.


Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.

Alper BJ, Rowse JW, Schmidt WK.

Yeast. 2009 Nov;26(11):595-610. doi: 10.1002/yea.1709.


Proteolytic processing of certain CaaX motifs can occur in the absence of the Rce1p and Ste24p CaaX proteases.

Krishnankutty RK, Kukday SS, Castleberry AJ, Breevoort SR, Schmidt WK.

Yeast. 2009 Aug;26(8):451-63. doi: 10.1002/yea.1678.


A capillary electrophoresis method for evaluation of Abeta proteolysis in vitro.

Alper BJ, Schmidt WK.

J Neurosci Methods. 2009 Mar 30;178(1):40-5. doi: 10.1016/j.jneumeth.2008.11.010. Epub 2008 Nov 21.


An excess of cosmic ray electrons at energies of 300-800 GeV.

Chang J, Adams JH, Ahn HS, Bashindzhagyan GL, Christl M, Ganel O, Guzik TG, Isbert J, Kim KC, Kuznetsov EN, Panasyuk MI, Panov AD, Schmidt WK, Seo ES, Sokolskaya NV, Watts JW, Wefel JP, Wu J, Zatsepin VI.

Nature. 2008 Nov 20;456(7220):362-5. doi: 10.1038/nature07477.


Small-molecule inhibitors of the Rce1p CaaX protease.

Manandhar SP, Hildebrandt ER, Schmidt WK.

J Biomol Screen. 2007 Oct;12(7):983-93.


Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones.

Porter SB, Hildebrandt ER, Breevoort SR, Mokry DZ, Dore TM, Schmidt WK.

Biochim Biophys Acta. 2007 Jun;1773(6):853-62. Epub 2007 Mar 20.


A common genetic system for functional studies of pitrilysin and related M16A proteases.

Alper BJ, Nienow TE, Schmidt WK.

Biochem J. 2006 Aug 15;398(1):145-52.


Mutational analysis of the ras converting enzyme reveals a requirement for glutamate and histidine residues.

Plummer LJ, Hildebrandt ER, Porter SB, Rogers VA, McCracken J, Schmidt WK.

J Biol Chem. 2006 Feb 24;281(8):4596-605. Epub 2005 Dec 17.


Yeast as a tractable genetic system for functional studies of the insulin-degrading enzyme.

Kim S, Lapham AN, Freedman CG, Reed TL, Schmidt WK.

J Biol Chem. 2005 Jul 29;280(30):27481-90. Epub 2005 Jun 8.


Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.

Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, Du W, Schmidt WK, Wallin BA; Alvimopan Postoperative Ileus Study Group.

Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9.


Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.

Paulson DM, Kennedy DT, Donovick RA, Carpenter RL, Cherubini M, Techner L, Du W, Ma Y, Schmidt WK, Wallin B, Jackson D.

J Pain. 2005 Mar;6(3):184-92.


AtFACE-2, a functional prenylated protein protease from Arabidopsis thaliana related to mammalian Ras-converting enzymes.

Cadiñanos J, Varela I, Mandel DA, Schmidt WK, Díaz-Perales A, López-Otín C, Freije JM.

J Biol Chem. 2003 Oct 24;278(43):42091-7. Epub 2003 Aug 19.


Identification, functional expression and enzymic analysis of two distinct CaaX proteases from Caenorhabditis elegans.

Cadiñanos J, Schmidt WK, Fueyo A, Varela I, López-Otín C, Freije JM.

Biochem J. 2003 Mar 15;370(Pt 3):1047-54.


Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect.

Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A, Meta M, Genant H, Jiang Y, Wisner ER, Van Bruggen N, Carano RA, Michaelis S, Griffey SM, Young SG.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13049-54. Epub 2002 Sep 16.


Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.

Schmidt WK.

Am J Surg. 2001 Nov;182(5A Suppl):27S-38S. Review.


The multispanning membrane protein Ste24p catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor precursor.

Tam A, Schmidt WK, Michaelis S.

J Biol Chem. 2001 Dec 14;276(50):46798-806. Epub 2001 Oct 1.


Biochemical studies of Zmpste24-deficient mice.

Leung GK, Schmidt WK, Bergo MO, Gavino B, Wong DH, Tam A, Ashby MN, Michaelis S, Young SG.

J Biol Chem. 2001 Aug 3;276(31):29051-8. Epub 2001 Jun 8.


The yeast a-factor transporter Ste6p, a member of the ABC superfamily, couples ATP hydrolysis to pheromone export.

Ketchum CJ, Schmidt WK, Rajendrakumar GV, Michaelis S, Maloney PC.

J Biol Chem. 2001 Aug 3;276(31):29007-11. Epub 2001 Jun 1.


Reconstitution of the Ste24p-dependent N-terminal proteolytic step in yeast a-factor biogenesis.

Schmidt WK, Tam A, Michaelis S.

J Biol Chem. 2000 Mar 3;275(9):6227-33.


Supplemental Content

Loading ...
Support Center